Has further downside to $11-$14 - Gap fill from October 19' Short

Descrizione

⋅ 10 feb 2020 21:43

The recent plummet was due to less than stellar Phase 3 results. With a March 25 PDUFA target on the horizon, longs may have given up and cut their losses. Technical indicate a big gap to fill in the $11-$14 area from October last year. Short.

Commenti

fsanyot1

⋅ 24 feb 2020 17:15

This is dumb. Their PDUFA is for a different disease (Dravet Syndrome) while the data is about Lennox-Gestaut syndrome. Long.

SimplyCash

⋅ 27 feb 2020 01:49

@fsanyot1, Still long?

Altro